Immunizing at birth is safe and effective against severe pneumococcal disease

August 26, 2011
Immunizing at birth is safe and effective against severe pneumococcal disease
Vaccinating children against the pneumococcus at birth is safe and primes the immune system against later infection, according to research published in the journal ‘Clinical Infectious Diseases’.

(Medical Xpress) -- Vaccinating children against the pneumococcus at birth is safe and primes the immune system against later infection, according to research published in the journal Clinical Infectious Diseases.

The study, carried out by researchers at the KEMRI-Wellcome Trust Research Programme in Kilifi, Kenya, working in collaboration with scientists at the UCL Institute of Child Health, indicates that immunising children within the first three days of life does not negatively affect their responses to a second or third dose of .

Babies born to HIV-negative mothers were given 7-valent pneumococcal at birth and then again at ten and 14 weeks of age. A second group received the vaccine at six, ten and 14 weeks, one of the schedules recommended by the World Health Organization (WHO).

The vaccine was found to be equally safe when administered to both groups. By 18 weeks the vaccine had induced a protective immune response in around nine out of ten infants in both groups. The researchers tested immune memory by giving a 'booster' vaccine at 36 weeks and found vigorous responses to the booster in both groups, indicating that inability to respond to a second or third dose of the vaccine (immune tolerance), a potential hazard of newborn vaccination, was not a problem in either group.

was estimated to cause 14.5 million episodes of illness and 826 000 deaths in children under the age of 5 years worldwide in the year 2000. The bacterium can cause illnesses including in the lungs, bacteraemia (infection of the blood) and meningitis.

More than half of these deaths occurred in Africa. In Kenya, the disease is common in toddlers aged under two years; 15 per cent of these disease episodes occur in the first two months of life, before babies are due to receive the first dose of the vaccine.

"The Kenya expanded immunisation programme has brought about huge for children in Kenya," explains Professor Fred Were, a neonatologist and National Chairman of the Kenya Paediatric Association. "However, the less-than-a-month-old babies remain the most at-risk population for many bacterial infections. This research shows that, in principle, we may be able to reach them earlier with an effective vaccine against pneumococcal disease."

Dr. Anthony Scott, a researcher with the KEMRI-Wellcome Trust Research Programme, adds: "While the results of this study are very encouraging, further research is required to establish whether the schedule negatively affects responses to other routine childhood vaccines and to explore whether the second and/or third doses can be delivered earlier."

Explore further: Clinical trial of malaria vaccine begins in Africa

More information: Scott JAG et al. Pneumococcal conjugate vaccine given shortly after birth stimulates effective antibody concentrations and primes immunological memory for sustained infant protection. Clin Infect Dis 2011 24 August [epub].

Related Stories

Clinical trial of malaria vaccine begins in Africa

May 25, 2011
The vaccine, RTS,S, developed by GlaxoSmithKline (GSK) Biologicals and PATH Malaria Vaccine Initiative (MVI), is currently in phase III clinical trials and has previously reduced episodes of malaria in infants and young children ...

TB trial highlights challenges with introducing new vaccine into childhood immunization schedule

June 22, 2011
A new vaccine to combat tuberculosis is less effective at stimulating an immune response when administered to Gambian infants in combination with the routine immunisation schedule, according to clinical trial results published ...

Recommended for you

Google searches can be used to track dengue in underdeveloped countries

July 20, 2017
An analytical tool that combines Google search data with government-provided clinical data can quickly and accurately track dengue fever in less-developed countries, according to new research published in PLOS Computational ...

MRSA emerged years before methicillin was even discovered

July 19, 2017
Methicillin resistant Staphylococcus aureus (MRSA) emerged long before the introduction of the antibiotic methicillin into clinical practice, according to a study published in the open access journal Genome Biology. It was ...

New test distinguishes Zika from similar viral infections

July 18, 2017
A new test is the best-to-date in differentiating Zika virus infections from infections caused by similar viruses. The antibody-based assay, developed by researchers at UC Berkeley and Humabs BioMed, a private biotechnology ...

'Superbugs' study reveals complex picture of E. coli bloodstream infections

July 18, 2017
The first large-scale genetic study of Escherichia coli (E. coli) cultured from patients with bloodstream infections in England showed that drug resistant 'superbugs' are not always out-competing other strains. Research by ...

Ebola virus can persist in monkeys that survived disease, even after symptoms disappear

July 17, 2017
Ebola virus infection can be detected in rhesus monkeys that survive the disease and no longer show symptoms, according to research published by Army scientists in today's online edition of the journal Nature Microbiology. ...

Mountain gorillas have herpes virus similar to that found in humans

July 13, 2017
Scientists from the University of California, Davis, have detected a herpes virus in wild mountain gorillas that is very similar to the Epstein-Barr virus in humans, according to a study published today in the journal Scientific ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.